We are maintaining a Neutral rating on Alkermes (NASDAQ:ALKS) with a target price of $18.00.
Last month, Alkermes released its third quarter fiscal 2012 (ended December 31, 2011) financial results.  This was the first full quarter for Alkermes plc, formed in September 2011, following the merger of Waltham, Massachusetts based Alkermes, Inc. and Elan Drug Technologies (EDT), the drug delivery unit of  Elan Corporation (NYSE:ELN). The merger has expanded the portfolio significantly resulting in … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards